on Evotec AG (NASDAQ:EVTCY)
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Evotec SE has announced a multi-year collaboration with Pfizer. The partnership will initially target early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse.
Evotec will receive research funding from Pfizer and may achieve milestones and royalties based on the program's success. Dr Matthias Evers of Evotec emphasizes the importance of the collaboration in addressing severe unmet medical needs with innovative therapeutic approaches.
Dr Luca Mollo of Pfizer highlights the significance of the partnership in advancing scientific discovery within France's strong biopharmaceutical ecosystem. The collaboration aims to develop new treatments for diseases affecting millions worldwide.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news